Cycc short interest
WebThomson Reuters StreetEvents -6.63%. Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment ... WebApr 10, 2024 · A high-level overview of Cyclacel Pharmaceuticals, Inc. (CYCC) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …
Cycc short interest
Did you know?
WebThe Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ... WebLive Short Interest data, Utilization, Cost to borrow and much more for Cyclacel Pharmaceuticals, Nasdaq:CYCC
WebOct 14, 2024 · CYCC Complete Cyclacel Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. WebApr 9, 2024 · 2 brokerages have issued 12 month price targets for Cyclacel Pharmaceuticals' stock. Their CYCC share price forecasts range from …
WebCompany’s earnings for a period net of operating costs, taxes, and interest. -7.42M. -40.14%. Net profit margin. Measures how much net income or profit is generated as a … WebThe Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of …
WebMembers receive 2 years of Historical Short Interest data (older historical data is available for purchase by members). Each report includes a comprehensive collection of in-depth short interest details. After every published short interest release, the data is compiled and made available for members to download and use (in Excel format).
WebApr 6, 2024 · CYCC Earnings Date and Information. Cyclacel Pharmaceuticals last issued its quarterly earnings results on March 6th, 2024. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.12. Cyclacel Pharmaceuticals has generated ($1.90) earnings per share over the … the twin forks dotaWebCyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. sew what willard chapel auburn nyWebCYCC Complete Cyclacel Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. sew what\u0027s new tv showWebShort Interest Funds Shorting CYCC Short Transactions Short Volume Fails to Deliver. Options. Options Chain Options Sentiment Options Flow Gamma Exposure Implied Volatility. Filings . SEC Filings - Categorized. Financials . Finpedia Article Metrics & Ratios Balance Sheet Income Statement Cash Flow Statement Piotroski Score. the twin flower legend ซับไทยWebFind the latest on short interest for Cyclacel Pharmaceuticals, Inc. Common Stock (CYCC) at Nasdaq.com. the twin flower legend vikiWebShort interest for Cyclacel Pharmaceuticals gives investors a sense of the degree to which investors are betting on the decline of Cyclacel Pharmaceuticals's stock. Short interest … sew what writeWebInstitutional Ownership and Shareholders. Cyclacel Pharmaceuticals Inc (US:CYCC) has 41 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). … the twin flower legend watch online